Login or sign up
For business

Proterris, inc

4.0· 10 reviews
Average ratingGreat
4.0/ 5

Based on 10 reviews

530%
440%
330%
20%
10%
Ask AI

Questions about Proterris, inc

Based on 10 reviews, listing data and website checks · updated 3 days ago

What is Proterris, inc?

Proterris, inc is a P2 clinical-stage biotechnology firm headquartered in Boston, Massachusetts. The company holds a dominant IP position in therapeutic uses of inhaled and small-molecule carbon monoxide. It is initially focused on using carbon monoxide to improve outcomes in solid organ transplantation. The firm has attracted over $50M in grant awards and equity financings to support its programs.

What specific medical conditions is Proterris, inc targeting with its carbon monoxide therapies?

The company is developing a portfolio of inhaled and small-molecule CO therapies targeting transplant, kidney, lung, and oncology indications. These programs address a potential patient population of over 20 million in the U.S. alone. The firm prioritizes CO development in delayed graft function, acute liver failure, and non-alcoholic steatohepatitis, with opportunities in acute kidney injury, renal fibrosis, and idiopathic pulmonary fibrosis.

Which academic and institutional partners were involved in founding Proterris, inc?

Proterris was co-founded by Apeiron Partners and a consortium of leading institutions. The founding partners include the University of Pittsburgh, Columbia University, Beth Israel Deaconess Medical Center, Johns Hopkins, and Yale University. This collaboration established the company's strong global IP position in carbon monoxide therapeutics.

What are the names of the specific science programs currently being developed by Proterris, inc?

The company's science programs include PRO-301, which focuses on DGF prevention in kidney transplant, and PRO-302, which targets PGD prevention in lung transplant. These initiatives utilize small molecule CO releasers as part of their therapeutic approach.

What scientific properties of carbon monoxide are cited as the basis for Proterris, inc's therapeutic approach?

Carbon monoxide is recognized for its cytoprotective, anti-inflammatory, and anti-fibrotic properties. Proterris believes CO stands out among therapeutic gasotransmitters due to its extensive preclinical validation across multiple disease areas. Beneficial effects are observed at doses well below known toxicity thresholds.

What philosophical principle regarding dosage does Proterris, inc attribute to Paracelsus?

The company's website states that all substances are poisons and the right dose differentiates a poison and a remedy, quoting Paracelsus. This philosophy underpins their development of inhaled and small-molecule CO therapies. The firm aims to leverage this principle to create effective treatments for serious conditions.

What specific aspects of the customer experience do reviewers frequently commend?

Reviewers on Trustburn consistently praise the company's website for being user-friendly, easy to navigate, and well-designed. Customers also highlight the excellent quality and outstanding performance of the company's products. Many users express high satisfaction with their experience and recommend the services.

What is the current Trustburn rating and the timeframe of the available reviews?

The Trustburn listing shows a rating of 4 out of 5 stars based on 10 reviews. The most recent review was posted on October 21, 2023, while the oldest review in the set dates back to December 30, 2022. The reviews span from late 2022 through late 2023.

What navigation sections and informational resources are available on the Proterris, inc website?

The company's website includes sections for Management Board, Co-Founders & Advisors, Science Programs, and News/Presentations. Visitors can access information about the pipeline, including specific drug candidates like PRO-301 and PRO-302. A contact form or page is available for inquiries.

What industry classification and geographic location define Proterris, inc?

Proterris, inc operates in the biotechnology industry and is classified as a P2 clinical-stage firm. The business is located in Boston, Massachusetts, serving the United States market. The firm focuses on clinical-stage development rather than commercial distribution at this stage.

What is the core intellectual property advantage of Proterris, inc?

The company holds a strong global IP position in the therapeutic uses of inhaled and small-molecule carbon monoxide. This intellectual property portfolio supports their development of small molecule CO releasers. The firm has pooled a dominant IP position to advance its pipeline.

What common themes emerge from the customer reviews regarding product and service quality?

Some reviewers note that the website is intuitive and well-crafted, contributing to a positive user experience. The products are described as top-notch and of unparalleled quality by satisfied customers. The services provided are considered truly exceptional by many users.

What is the scale of the potential patient population Proterris, inc aims to serve?

The company aims to address a potential patient population of over 20 million in the U.S. alone through its oncology, transplant, kidney, and lung indications. This large addressable market is a key driver for their scientific programs. The firm targets significant opportunities in a number of other indications beyond their primary focus.

What level of funding and team composition does Proterris, inc claim to have?

The firm has attracted over $50M of grant awards and equity financings thus far to support its programs. This funding supports the development of their portfolio of inhaled and small-molecule CO therapies. The company is described as having a proven, top-tier team of company builders and clinical development leaders.

How does Proterris, inc describe the safety profile of their carbon monoxide therapies?

The company's website states that CO is increasingly recognized for its beneficial effects at doses well below known toxicity thresholds. This safety profile is highlighted as a distinguishing feature of their therapeutic gasotransmitter approach. The firm emphasizes that the right dose differentiates a poison and a remedy.

AI-generated from reviews on this page. Verify anything important with the company directly.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About Proterris, inc

Proterris, a P2 clinical-stage firm, has pooled a dominant IP position in therapeutic uses of inhaled and small-molecule carbon monoxide. Proterris has prioritized CO development in delayed graft function (DGF), acute liver failure, and non-alcoholic steatohepatitis (NASH), with significant opportunities in a number of other indications, including but not limited to acute kidney injury (AKI), renal fibrosis, and idiopathic pulmonary fibrosis (IPF).

It is headquartered in Boston, Massachusetts.

Categories
Biotechnology